Early Detection Research Network


EIF3E is one of the most statistically significant antigens in terms of its contribution to classification performance, along with SF3A1, and MYOZ2. (PMID:20977275) Additionally, data from another study suggests that eIF3e has a positive role in breast cancer progression. It regulates the translation, and in some cases abundance, of mRNAs involved in key aspects of cancer cell biology. (PMID:20453879)
Under Review
EIF3E is a member of a 28 autoantibody (AAb) classifier that was developed with a sensitivity of 80.8% and a specificity of 61.6% (AUC=0.756). The 28 autoantibodies are potential biomarkers for breast cancer both individually and as members of the classifier.
Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement

The overall goal of this project application for the EDRN set-aside funds is to focus our collaborative efforts to identify p53 mutation-specific antibody biomarkers in breast, prostate, and ovarian cancer. P53-specific gene mutations are frequent in multiple cancer types. Of the common solid tumors, p53 mutations have been identified in 50% of lung and ovarian cancers, 45% of colon cancers, 20% of breast cancers, and 10-30% of prostate cancers (The p53 Mutation Handbook, T. Soussi, http://p53/free/fr). The most common mutations vary from cancer to cancer, with 50 point mutations covering the 10 most common mutations for all major solid tumors